April Armstrong, MD, MPH, of University of California, Los Angeles, explained that the main health care gap within the atopic dermatitis (AD) realm is that many clinicians are not comfortable prescribing systemic medications.
April Armstrong, MD, MPH, professor and chief of dermatology at University of California, Los Angeles, identified gaps when treating moderate to severe atopic dermatitis (AD), including the lack of clinicians comfortable with prescribing patients systemic medications.
Transcript
What are some of the main health care gaps you are seeing in either your own practice or more generally when treating moderate to severe AD?
I think some of the health care gaps that we see in treating patients with moderate to severe [AD] as a field are still that we don't have that many clinicians comfortable in prescribing, for example, systemic medications for these patients who warrant systemic medications.
I think that we, as a field, are improving over time in terms of our comfort with these different types of medications, but when we look at the scope of how many patients are affected vs how many of them are actually on adequate therapy, there is a gap. Now, when we look at that gap, there can be a number of reasons. One is potentially the clinicians may not be as comfortable; the other is, of course, insurance coverage for these medications. Many of them would require insurance coverage for patients to have any access to it, so I think that is important to consider.
Then, finally, I think, for patients, too, it's important to augment our education in general for our patients so they understand how these newer medications work for them, what they can do, what the safety profile looks like. I think it's a multipronged problem, and so, in order to close the gap, we want to close and then address each of these different prongs to this problem.
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Adapting ACA Access Amid Medicaid Transition and Policy Reversals: Molly Dean
February 19th 2025As enrollment shifts to the Affordable Care Act (ACA) marketplace following the unwinding of Medicaid and the Trump administration begins to implement health policy changes, Molly Dean, MSW, Siftwell's policy advisor, shares insight on how to adapt.
Read More